The latest price target for VolitionRX (AMEX:VNRX) was reported by D. Boral Capital on January 21, 2026. The analyst firm set a price target for $3.00 expecting VNRX to fall to within 12 months (a possible NaN% downside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for VolitionRX (AMEX:VNRX) was provided by D. Boral Capital, and VolitionRX maintained their buy rating.

There is no last upgrade for VolitionRX

The last downgrade for VolitionRX Ltd happened on December 3, 2025 when Maxim Group changed their price target from N/A to N/A for VolitionRX Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VolitionRX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VolitionRX was filed on January 21, 2026 so you should expect the next rating to be made available sometime around January 21, 2027.

While ratings are subjective and will change, the latest VolitionRX (VNRX) rating was a maintained with a price target of $3.00 to $3.00. The current price VolitionRX (VNRX) is trading at is $undefined, which is out of the analyst’s predicted range.